Sexually transmitted infections (STIs) have been increasing in the United States. Evidence suggests that taking doxycycline after condomless sex can reduce the risk of STIs, especially among transgender women and men who have sex with men. Studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI) showed promising results, but questions remain about its effectiveness for cisgender women and its impact on resistant gonorrhea. While doxy-PEP could be an important STI prevention tool, adherence and strategies for distribution need to be further explored. The data from various studies suggest that a wider rollout of doxy-PEP could have a significant impact on reducing STI rates.
Source link
New evidence ‘seals the case’ for doxy-PEP as STI prevention tool
